Art. -Nr.: HY-N7046

Silybin B

(Synonyms: Silibinin B)

Kundenbewertung

Based on 1 Customer Validation

Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.90%
CAS. Nr.: 142797-34-0
Formel: C₂₅H₂₂O₁₀
Molecular Weight:482.44

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Silybin B Chemical Structure

CAS. Nr.: 142797-34-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle p38 MAPK Isoform-spezifische Produkte anzeigen :

Alle JNK Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
B16-4A5	IC₅₀	>100 μM Compound: 6	Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay	[PMID: 20189399]
DU-145	IC₅₀	61.8 μM Compound: 1	Antiproliferative activity against human DU145 cells after 72 hrs after ATPlite kit assay Antiproliferative activity against human DU145 cells after 72 hrs after ATPlite kit assay	[PMID: 23260576]
HEK293	IC₅₀	5 μM Compound: Silybin B	Inhibition of OATP1B3 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]estradiol-17beta-glucuronide uptake after 3 mins by beta-counting Inhibition of OATP1B3 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]estradiol-17beta-glucuronide uptake after 3 mins by beta-counting	[PMID: 23401473]
HEK293	IC₅₀	8.5 μM Compound: Silybin B	Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]estradiol-17beta-glucuronide uptake after 3 mins by beta-counting Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]estradiol-17beta-glucuronide uptake after 3 mins by beta-counting	[PMID: 23401473]
Huh-7	IC₅₀	40 μM Compound: 1	Antiviral activity against HCV JFH1 infected in human Huh7.5.1 cells assessed as reduction in viral proteins after 72 hrs post compound dose by Western blotting method Antiviral activity against HCV JFH1 infected in human Huh7.5.1 cells assessed as reduction in viral proteins after 72 hrs post compound dose by Western blotting method	[PMID: 23260576]
Huh-7	IC₅₀	56.2 μM Compound: 1	Antiproliferative activity against human Huh7.5.1 cells after 72 hrs after ATPlite kit assay Antiproliferative activity against human Huh7.5.1 cells after 72 hrs after ATPlite kit assay	[PMID: 23260576]
Huh-7	IC₅₀	68.7 μM Compound: 3	Cytotoxicity against human Huh7.5.1 cells after 72 hrs Cytotoxicity against human Huh7.5.1 cells after 72 hrs	[PMID: 23673225]
Huh7.5.1	CC₅₀	68.7 μM Compound: 4	Cytotoxicity against human Huh7.5.1 cells after 72 hrs by ATPlite assay Cytotoxicity against human Huh7.5.1 cells after 72 hrs by ATPlite assay	[PMID: 30485098]
HUVEC	IC₅₀	6.49 μM Compound: 1b, (2R,3R,10S,11S)	Antiproliferative activity against HUVEC assessed as inhibition of cell growth after 3 days by MTT assay Antiproliferative activity against HUVEC assessed as inhibition of cell growth after 3 days by MTT assay	[PMID: 21928794]
HUVEC	IC₅₀	60.47 μM Compound: 1b, (2R,3R,10S,11S)	Cytotoxicity against HUVEC assessed as cell viability after 16 hrs by MTT assay Cytotoxicity against HUVEC assessed as cell viability after 16 hrs by MTT assay	[PMID: 21928794]
LNCaP	IC₅₀	69.6 μM Compound: 1	Antiproliferative activity against human LNCAP cells after 72 hrs after ATPlite kit assay Antiproliferative activity against human LNCAP cells after 72 hrs after ATPlite kit assay	[PMID: 23260576]
MDCK-II	IC₅₀	0.8 μM Compound: Silybin B	Inhibition of OATP2B1 (unknown origin) expressed in MDCK2 cells assessed as reduction of [3H]estrone-3-sulfate uptake after 3 mins by beta-counting Inhibition of OATP2B1 (unknown origin) expressed in MDCK2 cells assessed as reduction of [3H]estrone-3-sulfate uptake after 3 mins by beta-counting	[PMID: 23401473]
PC-3	IC₅₀	60.5 μM Compound: 1	Antiproliferative activity against human PC3 cells after 72 hrs after ATPlite kit assay Antiproliferative activity against human PC3 cells after 72 hrs after ATPlite kit assay	[PMID: 23260576]

In Vitro

Silybin B (4 μM; 24 h) inhibits amyloid fibril formation, promoted amorphous aggregate formation, and reduces ThT fluorescence intensity in 10 μM Aβ40 solution^[1].
Silybin B (20, 40, 80 μM; 48 h) dose-dependently antagonizes the cytotoxicity of 10 μM Cisplatin (HY-17394), and increases HT22 cell viability, reduces cell arrest in the G2/M phase, reduces cell apoptosis, and increases cleaved-PARP protein expression^[2].
Silybin B (20, 40, 80 μM; 24 h) inhibits protein phosphorylation in the JNK/p38 MAPK signaling pathway in HT22 cells, upregulates p-ATR protein expression and downregulates γ-H2AX levels, and alleviates DNA damage^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

Murine hippocampal neuronal HT22 cells
Concentration:

20 μM, 40 μM, 80 μM
Incubation Time:

48 h
Result:

Dose-dependently increased cell viability in cisplatin (10 μM)-treated HT22 cells.
Compared to the cisplatin-alone group, cell viability increased from 30% to 60% (20 μM) and 70% (80 μM), indicating alleviation of cisplatin-induced cytotoxicity.

In Vivo

Silybin B (50 μM; fed; single; 24 h) reduces the production of Aβ oligomers and significantly decreases the paralysis rate in a transgenic C. elegans nematode paralysis model expressing human Aβ42^[1].
Silybin B (25, 50 mg/kg; gavage; once a day; 15 days) increases the antioxidant indexes of SOD, GSH, and T-AOC in the brain, reduces the level of LPO, and alleviates neuronal damage and apoptosis in the hippocampus in a Cisplatin (HY-17394)-induced mouse neurotoxicity model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Balb/c mice (6-7 weeks old) with Cisplatin-induced neurotoxicity model^[2]
Dosage:

25 mg/kg, 50 mg/kg
Administration:

Oral gavage, daily for 15 consecutive days, with a single intraperitoneal injection of Cisplatin (10 mg/kg) on day 10
Result:

Significantly improved motor coordination and learning memory in Cisplatin-treated mice, as evidenced by reduced escape latency in the Morris water maze and decreased time to descend the pole test.
I ncreased the levels of superoxide dismutase (SOD), reduced glutathione (GSH), and total antioxidant capacity (T-AOC) in brain tissue, while decreased lipid peroxidation (LPO) levels.

Chemical Information

CAS. Nr. 142797-34-0
Appearance Solid
Molecular Weight 482.44
Formel C₂₅H₂₂O₁₀
Color White to off-white
SMILES

O=C1[C@H](O)[C@@H](C2=CC=C(O[C@@H](CO)[C@H](C3=CC=C(O)C(OC)=C3)O4)C4=C2)OC5=CC(O)=CC(O)=C15
Synonyms

Silibinin B
Structure Classification
- Flavonoids
- Flavanonols
- Phenols
- Polyphenols
Initial Source
- Plants
- Compositae
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 250 mg/mL (518.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0728 mL

10.3640 mL

20.7280 mL

5 mM

0.4146 mL

2.0728 mL

4.1456 mL

10 mM

0.2073 mL

1.0364 mL

2.0728 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.31 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.31 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.31 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Sciacca MFM, et al. Inhibition of Aβ Amyloid Growth and Toxicity by Silybins: The Crucial Role of Stereochemistry. ACS Chem Neurosci. 2017 Aug 16;8(8):1767-1778. [Content Brief]

[2]. Wang XL, et al. Silybin B exerts protective effect on cisplatin-induced neurotoxicity by alleviating DNA damage and apoptosis. J Ethnopharmacol. 2022 Apr 24;288:114938. [Content Brief]

[3]. An-Shen Lin, et al. Cancer Preventive Agents. 7. Antitumor-Promoting Effects of Seven Active Flavonolignans from Milk Thistle (Silybum marianum.) on Epstein-Barr Virus Activation, Pharmaceutical Biology, 45:10, 735-738.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0728 mL	10.3640 mL	20.7280 mL	51.8199 mL
	5 mM	0.4146 mL	2.0728 mL	4.1456 mL	10.3640 mL
	10 mM	0.2073 mL	1.0364 mL	2.0728 mL	5.1820 mL
	15 mM	0.1382 mL	0.6909 mL	1.3819 mL	3.4547 mL
	20 mM	0.1036 mL	0.5182 mL	1.0364 mL	2.5910 mL
	25 mM	0.0829 mL	0.4146 mL	0.8291 mL	2.0728 mL
	30 mM	0.0691 mL	0.3455 mL	0.6909 mL	1.7273 mL
	40 mM	0.0518 mL	0.2591 mL	0.5182 mL	1.2955 mL
	50 mM	0.0415 mL	0.2073 mL	0.4146 mL	1.0364 mL
	60 mM	0.0345 mL	0.1727 mL	0.3455 mL	0.8637 mL
	80 mM	0.0259 mL	0.1295 mL	0.2591 mL	0.6477 mL
	100 mM	0.0207 mL	0.1036 mL	0.2073 mL	0.5182 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Silybin B

MCE Bioactive Compound Library

Natural Product Library Plus

Alle p38 MAPK Isoform-spezifische Produkte anzeigen

Alle JNK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Silybin B

MCE Bioactive Compound Library

Natural Product Library Plus

Alle p38 MAPK Isoform-spezifische Produkte anzeigen

Alle JNK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Silybin B Related Classifications

HY-N7046 Related Classifications